On April 13, 2010 the Food and Drug Administration issued a drug safety communication titled: Questions and Answers: Phase-Out of CFC Metered-Dose Inhalers Containing flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil

Update about a follow-up to an October 2009 Public Health Alert about changes to the United States Pharmacopeia or USP monograph for heparin sodium.

Update about an ongoing safety review of Stalevo and an increased risk for developing prostate cancer.

The U.S. Food and Drug Administration (FDA) is reviewing data, submitted in August 2009, from a large, long-term clinical study on possible cardiovascular risks with the diabetes drug, Avandia (rosiglitazone).

The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the drug label for Plavix.

Healthcare professionals may have questions about oral bisphosphonate medications and atypical subtrochanteric femur fractures – fractures in the bone just below the hip joint.

The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals about a rare, but serious adverse event in the liver, non-cirrhotic portal hypertension, associated with the use of didanosine, marketed as Videx and Videx EC, a delayed-release version of Videx.

The U.S. Food and Drug Administration (FDA) is reviewing data about a potentially serious effect on the heart from the use of Invirase (saquinavir) in combination with Norvir (ritonavir).

The U.S. Food and Drug Administration (FDA) has received five reports of serious medication errors involving consumers who used Maalox Total Relief, the upset stomach reliever and anti-diarrheal medication, by mistake, when they had intended to use one of the traditional Maalox liquid antacid products.

On February 18, 2010 the Food and Drug Administration issued a drug safety communication titled: Questions and Answers: New Safety Requirements for Long-Acting Asthma Medications called Long-Acting Beta Agonists (LABAs)